Loading clinical trials...
Loading clinical trials...
A Randomized, Sham-controlled Pilot Trial of a Novel Therapeutic Strategy (taVNS) for Autonomic Nervous System (ANS) Dysfunction in Chronic Kidney Disease (CKD)
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
NYU Langone Health
New York, New York, United States
Start Date
October 15, 2025
Primary Completion Date
January 31, 2029
Completion Date
January 31, 2029
Last Updated
December 31, 2025
30
ESTIMATED participants
Active taVNS
DEVICE
Sham taVNS
DEVICE
Lead Sponsor
NYU Langone Health
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07358572